NeOnc Technologies Completes $18.5 Million Financing, Advances Phase II Clinical Trials for Enhanced Method of Delivering Novel Therapeutics to the Brain Under FDA Fast-Track Status

Quick Summary:

Two Phase II and one Phase I clinical studies advance after several published studies indicate NEO™ drug viability as a delivery vehicle for chemotherapeutics and ability to beneficially effect brain cancer treatment.WESTLAKE VILLAGE, Calif., June 26, 2024 (GLOBE NEWSWIRE) --  NeOnc Technologies Holdings, Inc., a clinical-stage medical biotechnology company, has completed a $18.5 million financing to support the ongoing development and Phase I and II clinical studies of its novel drug and delivery methods designed to address the persistent challenges with overcoming the blood-brain barrier.

Financing supports further expansion of NeOnc’s NEO™ platform technology that has produced a patent portfolio of novel drug candidates and delivery methods for more effectively passing the blood brain barrier.

It also opens the door to a number of options we now enjoy for accessing the capital markets that would be most favorable to our investors and invested management team.” According to NeOnc’s founder, CEO and CSO, Thomas Chen, M.D., Ph.D.: "Most importantly, the funding supports our mission of improving and extending the lives of brain cancer patients by developing therapies that maximize the effectiveness and delivery of current standard-of-care drugs for brain cancer.” Dr.

Read Quick SummarySave Time

or

Article Details

Author / Journalist: NeOnc Technologies Holdings, Inc.

Category: Technology

Markets: ChinaMali

Topics: TEMP12345678 Nasdaq:NTHI

Source Website Secure: Yes (HTTPS)

News Sentiment: Negative

Fact Checked: Legitimate

Article Type: News Report

Published On: 2024-06-26 @ 20:39:00 (3 days ago)

News Timezone: GMT +8:00

News Source URL: globenewswire.com

Language: English

Article Length: 1446 words

Reading Time: 9 minutes read

Sentences: 56 lines

Sentence Length: 26 words per sentence (average)

Platforms: Desktop Web, Mobile Web, iOS App, Android App

Copyright Owner: © GlobeNewswire

News ID: 21396418

View Article Analysis

About GlobeNewswire

Main Topics: Technology

Official Website: globenewswire.com

Year Established: 1998

Headquarters: China

News Last Updated: 1 days ago

Coverage Areas: China

Ownership: Independent Company

Publication Timezone: GMT +8:00

Content Availability: Worldwide

News Language: English

RSS Feed: Available (XML)

API Access: Available (JSON, REST)

Website Security: Secure (HTTPS)

Publisher ID: #116

Publisher Details

Frequently Asked Questions